NEWS★ LIFE SCIENCES / BIOTECHNOV 10, 2026
Neobe raises $6.8m to develop tumour-targeting bacteria
A cancer treatment cannot help if it struggles to reach the tumour.

A cancer treatment cannot help if it struggles to reach the tumour.
What happened
Neobe announced a $6.8m seed round led by ARC Ventures, with participants including Faber and Macmillan Ventures. Funding supports engineered bacteria intended to break down physical barriers that limit cancer drugs' access to solid tumours.
Why it matters
The approach aims to complement existing treatments by changing the environment around a tumour. It targets a different part of the problem from designing another drug to attack cancer cells.
The bigger picture
Development now needs to establish safety, delivery and clinical benefit. The financing provides resources to advance that work.
